A new therapeutic may be more effective against a variety of cancers--including colon, head and neck, mesothelioma, ovarian and pancreatic cancers--than previously thought.
Mode Diagnostics wants European regulatory approval in 2013 for a do-it-your-self home test for colon cancer, with an eye toward an FDA-signoff within18 months thereafter. And that's big news for the industry at large.
Researchers from a consortium in the Basque region of Spain and France have developed a compound that has stopped colon cancer metastasis in mice.
Lab21 says it is unloading its South Carolina clinical services business in order to focus more on its diagnostics business. The buyers: Local management and investors under the name Reedy Acquisitions.
Kyoto University scientists say they've successfully linked a biomarker to colon cancer stem cells in a mouse study, offering another potential way to develop a targeted cancer treatment with minimal side effects.
A pair of newly discovered genetic biomarkers from Australian company Clinical Genomics has caught the eye of Quest Diagnostics, and the diagnostics company has exercised its commercial option to license these markers to develop a new generation of blood-based colon cancer tests for the U.S. market.
A group of Spanish institutions are collaborating to develop an early test for colorectal cancer, the second-highest cause of cancer death in the Western world, killing 50,000 people every year.
As part of a partnership with biotech Genentech, University of Minnesota researchers have found gene mutations that could lead to personalized medicine for some types of colon cancer. The research is published online in the leading journal Nature .
After a mouse study and close scrutiny of more than 70 pairs of human tumors, Genentech geneticists and University of Minnesota Medical School scientists spotted two new genetic markers that could be a crucial red flag for some types of colon cancer. The hope is that the finding could eventually lead to more personalized, gene-specific colon cancer treatments.
Plans call for raising $50.2 million from an underwritten public offering of 5.5 million shares of common stock.